X
Search Filters
Format Format
Subjects Subjects
Subjects Subjects
X
Sort by Item Count (A-Z)
Filter by Count
life sciences & biomedicine (45) 45
science & technology (45) 45
humans (40) 40
oncology (36) 36
bevacizumab (26) 26
middle aged (24) 24
female (23) 23
male (23) 23
adult (21) 21
glioblastoma multiforme (21) 21
neurosciences & neurology (21) 21
clinical neurology (20) 20
glioblastoma (20) 20
newly diagnosed (20) 20
aged (18) 18
glioblastoma - drug therapy (18) 18
brain neoplasms - drug therapy (17) 17
temozolomide (17) 17
care and treatment (16) 16
newly diagnosed glioblastoma (16) 16
newly-diagnosed glioblastoma (15) 15
radiotherapy (15) 15
brain neoplasms - pathology (14) 14
dacarbazine - analogs & derivatives (14) 14
medicine & public health (14) 14
glioblastoma - pathology (13) 13
treatment outcome (13) 13
clinical trials (12) 12
gliomas (12) 12
neurology (12) 12
angiogenesis inhibitors - therapeutic use (11) 11
brain neoplasms - therapy (11) 11
chemotherapy (11) 11
glioblastoma - therapy (11) 11
prognosis (11) 11
radiation (10) 10
survival (10) 10
cancer (9) 9
combined modality therapy (9) 9
dacarbazine - administration & dosage (9) 9
follow-up studies (9) 9
antineoplastic combined chemotherapy protocols - therapeutic use (8) 8
disease-free survival (8) 8
glioblastoma - mortality (8) 8
magnetic resonance imaging (8) 8
brain neoplasms - mortality (7) 7
brain neoplasms - radiotherapy (7) 7
brain tumors (7) 7
dacarbazine - therapeutic use (7) 7
glioblastoma - radiotherapy (7) 7
malignant glioma (7) 7
survival rate (7) 7
young adult (7) 7
angiogenesis inhibitors (6) 6
antibodies, monoclonal, humanized - therapeutic use (6) 6
antimitotic agents (6) 6
antineoplastic agents (6) 6
bevacizumab - therapeutic use (6) 6
cancer research (6) 6
dacarbazine - adverse effects (6) 6
drug therapy (6) 6
glioblastoma - diagnosis (6) 6
glioma (6) 6
patient outcomes (6) 6
product development (6) 6
radiation therapy (6) 6
surgery (6) 6
tumors (6) 6
usage (6) 6
analysis (5) 5
angiogenesis inhibitors - adverse effects (5) 5
chemoradiotherapy (5) 5
hematology, oncology and palliative medicine (5) 5
patients (5) 5
recurrent (5) 5
recurrent glioblastoma (5) 5
research (5) 5
abridged index medicus (4) 4
angiogenesis (4) 4
angiogenesis inhibitors - pharmacology (4) 4
antineoplastic agents - therapeutic use (4) 4
brain cancer (4) 4
brain neoplasms - diagnosis (4) 4
brain neoplasms - diagnostic imaging (4) 4
brain neoplasms - metabolism (4) 4
development and progression (4) 4
dna methylation (4) 4
drug administration schedule (4) 4
glioblastoma - metabolism (4) 4
glioma - drug therapy (4) 4
irinotecan (4) 4
kaplan-meier estimate (4) 4
lomustine (4) 4
magnetic resonance imaging - methods (4) 4
medical prognosis (4) 4
molecular targeted therapy (4) 4
neoplasm recurrence, local - pathology (4) 4
overall survival (4) 4
radiology, nuclear medicine & medical imaging (4) 4
retrospective studies (4) 4
more...
Language Language
Publication Date Publication Date
Click on a bar to filter by decade
Slide to change publication date range


JAMA : the journal of the American Medical Association, ISSN 0098-7484, 12/2017, Volume 318, Issue 23, pp. 2306 - 2316
Journal Article
The lancet oncology, ISSN 1470-2045, 08/2014, Volume 15, Issue 9, pp. 943 - 953
Summary Background Treatment options for recurrent glioblastoma are scarce, with second-line chemotherapy showing only modest activity against the tumour... 
Hematology, Oncology and Palliative Medicine | MALIGNANT GLIOMA | SURVIVAL | EFFICACY | NEWLY-DIAGNOSED GLIOBLASTOMA | RESPONSE ASSESSMENT | IRINOTECAN | PATTERNS | II TRIAL | RADIOTHERAPY | ADJUVANT TEMOZOLOMIDE | Life Sciences & Biomedicine | Oncology | Science & Technology | Follow-Up Studies | Humans | Lomustine - adverse effects | Middle Aged | Brain Neoplasms - pathology | Neoplasm Recurrence, Local - drug therapy | Male | Neoplasm Recurrence, Local - mortality | Bevacizumab | Dose-Response Relationship, Drug | Neoplasm Recurrence, Local - pathology | Young Adult | Antibodies, Monoclonal, Humanized - administration & dosage | Neoplasm Invasiveness - pathology | Adult | Female | Brain Neoplasms - mortality | Drug Therapy, Combination | Antibodies, Monoclonal, Humanized - adverse effects | Drug Administration Schedule | Administration, Oral | Glioblastoma - therapy | Disease-Free Survival | Maximum Tolerated Dose | Glioblastoma - pathology | Adolescent | Brain Neoplasms - therapy | Survival Analysis | Infusions, Intravenous | Neoplasm Staging | Glioblastoma - mortality | Lomustine - administration & dosage | Drug Combinations | Antimitotic agents | Care and treatment | Relapse | Chemotherapy | Clinical trials | Lomustine | Product development | Antineoplastic agents | Glioblastoma multiforme | Diseases | Cancer | Index Medicus
Journal Article
Journal Article
Journal of neuro-oncology, ISSN 1573-7373, 12/2009, Volume 98, Issue 1, pp. 93 - 99
Journal Article
Journal of neuro-oncology, ISSN 0167-594X, 01/2017, Volume 131, Issue 1, pp. 11 - 20
Journal Article
International journal of radiation oncology, biology, physics, ISSN 0360-3016, 2008, Volume 71, Issue 5, pp. 1372 - 1380
Journal Article
Neuro-oncology (Charlottesville, Va.), ISSN 1522-8517, 03/2017, Volume 19, Issue 3, pp. 430 - 439
Journal Article
Journal of neuro-oncology, ISSN 0167-594X, 1/2015, Volume 121, Issue 2, pp. 331 - 339
Journal Article